{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:58:50Z","timestamp":1769839130439,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,1,12]],"date-time":"2006-01-12T00:00:00Z","timestamp":1137024000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold>  <jats:italic>Objectives<\/jats:italic>:\u2002To evaluate early (&lt;100\u2003d) treatment\u2010related mortality (TRM) in autologous stem cell transplant (ASCT) recipients. <jats:italic>Patients<\/jats:italic>:\u2002Altogether 1482 adult patients received ASCT in six Finnish centres 1990\u20132003. The most common diagnoses were non\u2010Hodgkin's lymphoma (NHL) (<jats:italic>n<\/jats:italic>\u2003=\u2003542), multiple myeloma (MM) (<jats:italic>n<\/jats:italic>\u2003=\u2003528), breast cancer (BC) (<jats:italic>n<\/jats:italic>\u2003=\u2003132), Hodgkin's lymphoma (<jats:italic>n<\/jats:italic>\u2003=\u200386) and chronic lymphocytic leukaemia (CLL) (<jats:italic>n<\/jats:italic>\u2003=\u200363). <jats:italic>Results<\/jats:italic>:\u2002Forty\u2010two patients (2.8%) died from treatment\u2010related reasons &lt;100\u2003d from ASCT. The median time to death was 38\u2003d from ASCT (0\u201399). The risk of TRM varied according to the diagnoses. The highest risk was observed in patients with AL amyloidosis (24%) followed by NHL (4.4%) and MM (1.9%). No early TRM was observed in patients transplanted for BC or CLL. Infections were the cause of death in 16 patients (fungal 7, bacterial 6, viral 3). Organ toxicity was responsible for early death in 26 patients (heart 9, lungs 7, other 10). <jats:italic>Conclusions<\/jats:italic>:\u2002This nation\u2010wide survey indicated a low early TRM in ASCT recipients in general, but higher risks in patients with AL amyloidosis or NHL. In addition to patient selection, also optimization of transplant procedure may be needed in these patient groups to reduce early TRM.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2005.00605.x","type":"journal-article","created":{"date-parts":[[2006,1,12]],"date-time":"2006-01-12T16:40:11Z","timestamp":1137084011000},"page":"245-250","source":"Crossref","is-referenced-by-count":51,"title":["Early treatment\u2010related mortality in adult autologous stem cell transplant recipients: a nation\u2010wide survey of 1482 transplanted patients"],"prefix":"10.1111","volume":"76","author":[{"given":"E.","family":"Jantunen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"It\u00e4l\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lehtinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Kuittinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Juvonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Koistinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Wiklund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Nousiainen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Remes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Volin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,1,12]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704653"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-05-1549"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704593"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-01-0298"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4192"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-140-2-200401200-00008"},{"key":"e_1_2_6_8_2","first-page":"523","article-title":"Patients >40 years undergoing autologous or allogeneic BMT have regimen\u2010related mortality rates and event\u2010free survivals comparable to patients <40 years","volume":"15","author":"Rapoport AP","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703712"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.1997.tb02200.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700713"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70020-6"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2004.00704.x"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02841-5"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.abbmt080666"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.4.1156"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703856"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.12.4276"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190400002251"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01208-1"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.3.731"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022340"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704288"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.03033.x"},{"key":"e_1_2_6_25_2","first-page":"973","article-title":"High\u2010dose therapy and autologous stem cell rescue for poor risk and reftactory lymphoma: a single centre experience of 123 patients","volume":"17","author":"Mahendra P","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1700772"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701820"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1702433"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11414"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/9.suppl_1.S15"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705266"},{"key":"e_1_2_6_32_2","first-page":"549","article-title":"High\u2010dose chemotherapy with BEAC regimen and autologous bone marrow transplantation for intermediate grade and immunoblastic lymphoma: durable complete remissions, but a high rate of regimen\u2010related toxicity","volume":"15","author":"Besien K","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02137-1"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-10-3863"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703757"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704946"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040125"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2005.00605.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2005.00605.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T05:40:24Z","timestamp":1697002824000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2005.00605.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,12]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1600-0609.2005.00605.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2005.00605.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,12]]}}}